Peptide and composition thereof for improving liver dysfunction

A composition and technology for liver disorders, applied in the field of peptides and compositions containing the peptides, can solve problems such as liver damage, and achieve the effects of preventing or improving liver disorders and preventing or improving liver dysfunction

Inactive Publication Date: 2012-12-05
香川恭一
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Currently, in the treatment of NAFLD, hyperlipidemia drugs such as fibrates, statins, and probucols, and antihypertensive drugs such as ARBs and ACE inhibitors are used. Insulin resistance-improving drugs such as pioglitazone and metformin have side effects and may cause liver damage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptide and composition thereof for improving liver dysfunction
  • Peptide and composition thereof for improving liver dysfunction
  • Peptide and composition thereof for improving liver dysfunction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0070] Example 2 Inhibitory effects of peptides on hepatic fat accumulation and liver fibrosis in B6N-NASH mice

[0071] In the early stage of NASH, it starts with fat, and in the later stage, it develops continuously in multi-stages of inflammation and fibrosis. There are several reports of animal models of liver fibrosis, but there are few animal models similar to the human condition. The effects of peptide WTQR and peptide ASLDK on hepatic fat accumulation and liver fibrosis were studied using the B6N-NASH model mouse recently developed as a model of human NASH liver fibrosis.

[0072] Specifically, N-acetyl-β-D-glucosaminidase inhibitor was administered to 2-day-old B6N-NASH mice purchased from Japan Charles River Co., Ltd. , and 6-week-old animals fed high-fat diet (manufactured by Lisaichi Daietto Co., Ltd., trade name: D12492) from 4 weeks old were used for the test (sick group) after 1 week of preliminary feeding. In addition, 6-week-old B6N-NASH mice not administ...

Embodiment 3

[0080] Example 3 Inhibitory effect of LPS-induced inflammatory cytokine production in RAW264 cells

[0081] The mouse-derived macrophage RAW264 cells were stimulated with lipopolysaccharide (LPS), which is considered an endotoxin, to induce inflammation, and the production levels of various inflammatory cytokines produced were studied.

[0082] Specifically, mouse-derived macrophage RAW264 cells suspended in 10% FBS-DMEM medium were mixed with 5×10 4 seeded per well in a 24-well plate. 24 hours after inoculation, each individual peptide listed in Table 2 (final concentration 0.5 mg / mL), Peptide mix I (each peptide contained in a final concentration of 0.3 mg / mL), or Peptide mix II was added as a test substance (The final concentration of each peptide included was 0.12 mg / mL), and LPS was added 48 hours after inoculation (final concentration: 100 ng / mL). The aforementioned Peptide mix I is a mixture of peptides WTQR and ASLDK, and Peptide mix II is a mixture of peptides WT...

Embodiment 4

[0092] Example 4 A mouse model of acute liver disorder induced by galactosamine and lipopolysaccharide

[0093] It is known that the combined use of galactosamine and lipopolysaccharide (LPS) can obtain an acute liver disorder model in which inflammation strongly develops. Using this model, the effects of peptide WTQR, peptide ASLDK, peptide FAK, peptide TSKY, peptide SDGLKH on inflammation were investigated.

[0094] Specifically, the peptides listed in Table 3 and Table 4 (WTQR, ASLDK, FAK, TSKY, and SDGLKH, dosage 50mg / kg body weight), Peptidemix I (the dosage of each peptide included is 30mg / kg body weight), or Peptide mix II (the dosage of each peptide included is 12mg / kg body weight) (According to the administered substance, it is called "WTQR injection group", "ASLDK injection group", "FAK injection group", "TSKY injection group", "SDGLKH injection group", "Peptide mix I injection group", and " Peptide mix II injection group"). The aforementioned Peptide mix I is ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a peptide and a composition thereof for improving liver dysfunction, wherein the peptide and the composition thereof can take a preventive effect or a curative effect on liver dysfunction and can be used for preparing drugs and food. The liver dysfunction particularly refers to a non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatosis hepatitis (NASH) or liver dysfunction caused by hepatitis viruses, alcohol, stress, drug or immunologic abnormality.

Description

technical field [0001] The present invention relates to a novel peptide and compositions containing the same. In addition, the present invention also relates to the use of the peptide and the composition containing the peptide for preventing or improving liver disorders. More specifically, the present invention relates to non-alcoholic fatty liver disease (Non-Alcoholic Fatty Liver Disease: NAFLD); non-alcoholic steatohepatitis (Non-Alcoholic Steato-Hepatitis: NASH) and hepatitis virus, alcohol, A peptide having preventive and ameliorating effects on various hepatic disorders caused by stress, drugs, or immune abnormalities, and a composition containing the peptide (composition for preventing or ameliorating hepatic disorders). Background technique [0002] NAFLD is the most common liver disease in developed countries. NAFLD contains a wide range of liver diseases, ranging from simple fatty liver to steatohepatitis and cirrhosis. NASH is a severe form of NAFLD, characteri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K5/117C07K19/00A61K38/07A61K38/08A61P1/16A23L1/29A61K38/06A23L33/00
CPCY02A50/30
Inventor 香川恭一福滨千津子笹川由香
Owner 香川恭一
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap